Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Ear, Nose, Mouth and ThroatDRG 150-epistaxis-with-mcc
    Ask Trek AI about this page

    Epistaxis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    DRG 150 addresses inpatient care for epistaxis with a Major Complication or Comorbidity, encompassing cases with substantial clinical complexity and higher resource needs. Accurate assignment influences Medicare inpatient reimbursement by directing higher-weighted payment under the Diagnosis-Related Group framework.

    Customize your policy alerts

    Sign up for drg 150 policy alerts

    Get alerted when payer policies referencing 150 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 150 Overview

    DRG 150 covers inpatient admissions for epistaxis, or nosebleed, when accompanied by a Major Complication or Comorbidity that significantly increases resource use and clinical complexity. This Diagnosis-Related Group typically applies when patients require intensive interventions, transfusions, or management of significant comorbid conditions. It matters for Medicare payment because the presence of a Major Complication or Comorbidity shifts reimbursement to a higher-weighted payment tier within the Medicare Severity Diagnosis-Related Group system. Proper assignment affects hospital payment for resource-intensive epistaxis cases.

    Table of contents

    Progress1 / 5

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    National Payment Rates

    Across the commercial payers shown, negotiated rates range from about $11K to $49K, with payer medians and quartiles varying by insurer; the widest spread is between Anthem (max $49K) and BCBS (median $11K). See the table and chart below for payer-specific distributions. Payer labels use full commercial names like Blue Cross Blue Shield, UnitedHealth Group, Cigna, Aetna, and Anthem for clarity.

    The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($12.7k), average submitted covered charges ($58.1k), average Medicare payment amount ($10.8k), and total discharges (726).

    Average Total PaymentAverage Submitted ChargesAverage Medicare PaymentTotal Discharges
    $13K$58K$11K730

    Patient Population

    This DRG’s population skews toward Medicare-age beneficiaries rather than primarily working-age patients, reflecting a predominance of older adults in the inpatient caseload. Commercial payers still cover a portion of cases, indicating a mixed but Medicare-leaning payer mix. Age distribution therefore trends toward the 65+ cohort rather than predominantly working-age adults.

    State Payment Rates

    State: Alaska1 / 49

    Alaska Benchmarks

    In Alaska, DRG 150 rates span from $21K to $32K across reported payers, with Anthem and Blue Cross Blue Shield clustered at $21K and Cigna at $32K. The most notable deviation from national averages is Cigna’s rate sitting well above the state’s other payers and above several national medians. See the table and chart below for payer-level detail.

    Key Insights for Alaska

    • Anthem is the highest-paying payer in Alaska at $21K, while BCBS (Blue Cross Blue Shield) also reports $21K and Cigna is higher at $32K; Cigna represents the highest payer in the state when compared across available payers and Anthem/BCBS the lowest.
    • Alaska’s payer rates range from $21K to $32K, with Cigna notably above the other state payers and exceeding typical national median levels for some payers, indicating a meaningful upward deviation versus many national benchmarks.

    Clinical Trials

    • Acute hemostatic intervention trials: randomized or prospective studies comparing immediate bleeding-control strategies in hospitalized adults with severe epistaxis complicated by major comorbidities (for example, patients with coagulopathy, on anticoagulation, or with significant cardiovascular disease). These studies evaluate time to hemostasis, need for transfusion, procedure rates (nasal packing, cautery, arterial ligation/embolization), and short-term complications, addressing the acute management decisions that determine length of stay and resource intensity. Results inform in-hospital protocols that directly affect inpatient reimbursement and resource allocation for high-acuity DRG 150 cases.
    • Comparative effectiveness and care pathway research: observational cohorts and pragmatic trials comparing different care pathways (emergency department-only vs. admission with ENT consult, early interventional radiology vs. surgical approaches, protocols for reversal of anticoagulation) in heterogeneous adult populations who present with epistaxis and major complications. These studies focus on outcomes such as rates of rebleeding, procedural utilization, ICU admission, and total hospitalization cost, helping payers and hospitals identify which pathways reduce complications and avoidable use of high-cost services. Findings guide clinical pathways and case management strategies to optimize DRG payments and minimize costly readmissions or extended stays.
    • Post-discharge outcomes and readmission prevention studies: cohort studies and quality-improvement trials following patients discharged after hospitalization for epistaxis with significant comorbidity to assess rates and predictors of 30- and 90-day readmission, delayed bleeding, thromboembolic events after anticoagulation management changes, and health-related quality of life. These investigations often target transitional care interventions (structured follow-up, anticoagulation clinic referral, patient education) in older adults and those with bleeding diatheses, providing evidence on interventions that reduce readmissions and downstream costs. This research is relevant to providers and payers because reducing readmissions and post-discharge complications improves overall outcomes and impacts total cost of care associated with DRG 150 episodes.

    Related Codes

    135-SINUS-AND-MASTOID-PROCEDURES-WITH-CC-MCC

    Sinus and Mastoid Procedures with CC/MCC: Inpatient Reimbursement Overview

    136-SINUS-AND-MASTOID-PROCEDURES-WITHOUT-CC-MCC

    Sinus and Mastoid Procedures without CC/MCC: Inpatient Reimbursement Overview

    137-MOUTH-PROCEDURES-WITH-CC-MCC

    Mouth Procedures with CC/MCC: Inpatient Reimbursement Overview

    138-MOUTH-PROCEDURES-WITHOUT-CC-MCC

    Mouth Procedures without CC/MCC: Inpatient Reimbursement Overview

    139-SALIVARY-GLAND-PROCEDURES

    Salivary Gland Procedures: Inpatient Reimbursement Overview

    140-MAJOR-HEAD-AND-NECK-PROCEDURES-WITH-MCC

    Major Head and Neck Procedures with MCC: Inpatient Reimbursement Overview

    141-MAJOR-HEAD-AND-NECK-PROCEDURES-WITH-CC

    Major Head and Neck Procedures with CC: Inpatient Reimbursement Overview

    142-MAJOR-HEAD-AND-NECK-PROCEDURES-WITHOUT-CC-MCC

    Major Head and Neck Procedures without CC/MCC: Inpatient Reimbursement Overview

    143-OTHER-EAR-NOSE-MOUTH-AND-THROAT-O-R-PROCEDURES-WITH-MCC

    Other Ear, Nose, Mouth and Throat O.R. Procedures with MCC: Inpatient Reimbursement Overview

    144-OTHER-EAR-NOSE-MOUTH-AND-THROAT-O-R-PROCEDURES-WITH-CC

    Other Ear, Nose, Mouth and Throat O.R. Procedures with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 24

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    Mean Rates by Payer — National — DRG 150
    Mean Rates by Payer — Alaska — DRG 150